U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07429864) titled 'Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide' on Sept. 12, 2025.
Brief Summary: HDV is an RNA virus that infects only in the presence of HBV, affecting about 13% of HBsAg carriers. In Italy, prevalence ranges from 3.2% to 9.3%. It increases the risk of cirrhosis, fulminant hepatitis, and HCC, particularly in high-risk groups (HIV, HCV, drug users, dialysis patients). Until 2020, pegIFN was the only therapy; since 2022, bulevirtide (BLV) has been available, blocking viral entry into hepatocytes and reducing HDV RNA and liver stiffness, with efficacy in 45-48% of patients, though the optima...